Navigation Links
Significant Advances in VCJD Prion Detection

Scientists have made significant advances towards the development of a technique that could be used to confirm whether someone is infected with variant CJD .

The technique, which has so far been used mainly in animal models, works by mimicking and accelerating the replication of prions - abnormal proteins that progressively kill off brain tissue and are thought to cause the disease.

The method, known as known as Protein Misfolding Cyclic Amplification (PMCA), enables the level of prions to be increased so that they can be recognised by existing detection methods.

Researchers have shown for the first time that the number of vCJD prions can be amplified from infected human brain tissue extracts prepared from normal human platelets - a type of blood cell essential for clotting.

The sample is incubated and exposed to repeated rounds of ultrasound, which break the prions up into more numerous smaller particles.

The research was carried out by the University of Edinburgh National CJD Surveillance Unit working with the Scottish National Blood Transfusion Service, the Neuropathogenis Unit at the Roslin Institute and CSL Behring, However, more research is urgently needed to ensure that the technique, which has been applied to brain tissue, can be applied to other tissues, such as blood, that might be used in tests for vCJD.

Professor James Ironside, of the National CJD Surveillance Unit at the University of Edinburgh, said: While this method, due to the length of time it takes to carry out, is unlikely to produce a rapid screening test that could be implemented in blood donation centres it may well be suitable as a confirmatory test that could be conducted at a national centre.

Work is currently ongoing to develop a screening test for vCJD but one of the issues common to various screening tests is that of false positive results.

By developing a reliable confirmatory t est, such as this one, the impact of these false positives can be minimised. However, the ethical dilemma remains over screening and testing for a disease for which there is no cure.

A total of 161 people have died from variant CJD since the disease emerged in early 1990, including three people who received blood transfusions from donors who later developed the disease.

There is therefore an urgent need to develop tests that may be used to screen blood donations for vCJD infectivity, backed up with confirmatory tests, to prevent further examples of disease spread through infected blood.


'"/>




Related medicine news :

1. Inhaled Corticosteroids Found To Have No Significant Effect On COPD
2. A Little Weight Loss Found To Make A Significant Difference In Men
3. New Drug Shows Significant Improvement In HIV-related Heart Condition
4. Patient Negligence - Significant Problem In The Early Detection Of Breast Cancer
5. Kidney Disease, More Significant Risk Factor For Heart Disease Than Obesity
6. Silicone Implants Make No Significant Difference To Breast Cancer Survivors
7. Biomarkers Could Prove Significant In Understanding Aging Process
8. Smoke From Cooking Fuels Cause A Significant Number Of Death Worldwide
9. Increased Nighttime BP, a Significant Predictor of Congestive Heart Failure
10. Significant Advance in Treatment of Breast Cancer Reported
11. Significant role of genetics in drug abuse, Norwegian study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... ... 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the ... new design of the shoulder pad. The shoulder pad provides optimal support and ... pain while using cold therapy. By utilizing ice and water that is circulated from ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... has recently contributed a medical article to the newly revamped Cosmetic Town ... article spotlights the hair transplant procedure known as Follicular Unit Extraction ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... RAPIDS, Mich. (PRWEB) , ... October 12, 2017 ... ... Wellness, has been named one of Michigan’s 2017 Best and Brightest in Wellness® ... and Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
(Date:9/19/2017)... , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing ... of targeted tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek ...
(Date:9/13/2017)... ATLANTA , Sept. 13, 2017   OrthoAtlanta ... to the Atlanta Football Host Committee (AFHC) for the 2018 ... Monday, Jan. 8, 2018, at Mercedes-Benz Stadium in ... part of the AFHC "I,m In" campaign, participating in many ... ...
Breaking Medicine Technology: